Marksans Pharma Limited — Investor Meet, 03-06-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Marksans Pharma delivered a robust Q4 FY26, with revenue up 20.8% YoY to ₹856 Cr, PAT soaring 64.3% YoY to ₹149 Cr, and EBITDA margin at 22.8%. Full-year FY26 revenue reached ₹2,951 Cr (+12.5% YoY), crossing ₹3,000 Cr in net income, with 20.4% EBITDA margin. Growth was strong across North America, UK/EU, and Australia/NZ, driven by new market entries and product launches. Management targets ₹4,000 Cr revenue by FY28, expecting 15-20% growth in FY27 with 20-21% EBITDA margins, despite rising raw material costs mitigated by inventory and forex. The company is actively exploring M&A to diversify, holding ₹990 Cr cash. A ₹0.90 per share dividend was declared.